Rob Dow, M.B.CH.B., F.R.C.P.E., F.F.P.M., serves as chief medical officer of PPD. In this role, he is responsible to the CEO for all aspects of human safety in PPD’s clinical trial programs. In addition, he directly manages the global product development and PPD® Consulting groups, which consult with clients to provide specialized, robust medical input and scientific assistance with the design and development of their clinical research programs and individual clinical trials.
Dr. Dow brings to his work 35 years of extensive medical and pharmaceutical experience. He has held senior positions at both large pharmaceutical companies and biotechnology companies, including Cell Genesys Inc. and F. Hoffmann-LaRoche. His achievements have included managing multidisciplinary teams that obtained regulatory approval for renal, heart and liver transplantation, refractory head and neck cancer, a protease inhibitor for HIV, a novel calcium channel blocker for angina and hypertension, a COMT-inhibitor for the treatment of Parkinsonism, a lipase inhibitor for obesity, the IDEC C2b8 antibody for the treatment of non-Hodgkin’s lymphoma, and a humanized anti-TAC antibody for the prevention of acute renal rejection.
He received his Bachelor of Medicine and Bachelor of Surgery (M.B.CH.B.) from the University of Dundee, Scotland, and has been a Fellow of the Royal College of Physicians of Edinburgh (F.R.C.P.E.) since 1991. Dr. Dow is also a founding member and, subsequently, Fellow of the Faculty of Pharmaceutical Medicine (F.F.P.M.), and an honorary Fellow of the Department of Medicine and Veterinary Science of Edinburgh University.